# Speclipse

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/speclipse

- Industry: Medical Devices & Equipment
- Headquarters: Gyeonggi-do, South Korea
- Website: www.speclipse.com
- Total disclosed funding: $11M
- Latest round: Series B (Aug 13, 2021)
- Investors on record: 9

## About

Based in South Korea, Speclipse, Inc. develops advanced cancer diagnostic solutions using Laser-Induced Plasma Spectroscopy (LIPS) and Artificial Intelligence (AI) technology to enhance dermatological diagnostics.Speclipse, Inc. was founded in 2015 in Gyeonggi-do, South Korea, focusing on innovative cancer diagnostics. The company is co-founded by Sung Pyun and Wanki Min, with Sung Pyun currently serving as CEO. Speclipse has successfully closed 6 deals, with its most recent funding round being Series B, in which they raised KRW 9 billion on August 13, 2021, from investors including BNH Investment, MiCo, Shinhan Capital, and Signite. The total amount raised by Speclipse amounts to KRW 9 billion.Speclipse, Inc. specializes in advanced cancer diagnostic solutions utilizing Laser-Induced Plasma Spectroscopy (LIPS) and Artificial Intelligence (AI) technology. Their flagship product, Spectra-Scope®, is a portable device that analyzes the biochemical properties of skin tissue to provide rapid oncological diagnostics. It employs a deep-learning AI-based diagnostic algorithm, enabling dermatologists to efficiently identify and treat various skin lesions. Additionally, Speclipse has developed innovative laser devices, Pico-K and Bellus-Q, for precise treatment of skin conditions, marketed primarily in the United States, South Korea, Europe, and Australia, catering to healthcare providers, dermatology clinics, and hospitals focused on skin cancer diagnostics and treatment.Speclipse, Inc. generates revenue through direct sales of its medical devices, particularly the Spectra-Scope®, along with its advanced laser treatments. Transactions are made through direct-to-consumer sales to dermatologists and medical facilities, where clients purchase devices and associated services. The company may also engage in partnerships with healthcare providers and clinics to broaden access to their technologies. Pricing structures vary, reflecting the specialized nature of their products, which may involve one-time purchases or service agreements for ongoing support. Their revenue model is closely linked to the effectiveness and reliability of their flagship products.Speclipse, Inc. plans to leverage the recent KRW 9 billion raised in their Series B funding round to enhance their product offerings and expand their market presence. The company is focused on the design and development of new products, specifically aiming to introduce additional diagnostic tools by mid-2023. Plans for expansion include entering new markets in Southeast Asia and Europe by late 2023, aiming to increase accessibility to their advanced diagnostic solutions.

## Funding rounds

- Series B, Aug 13, 2021, $7.7M — Shinhan Capital, BNH Investment, Signite, MiCo
- Series A, Oct 1, 2016, $2.7M — InterVest, SBVA, JB Investment
- Seed, Oct 1, 2015, $0.1M — Bluepoint Partners, Korea Tech Incubator for Startup

## Investors

- Bluepoint Partners (https://capitalatlas.ai/funds/bluepoint-partners) — Seed
- Korea Tech Incubator for Startup — Seed
- InterVest (https://capitalatlas.ai/funds/intervest) — Series A
- SBVA (https://capitalatlas.ai/funds/sbva) — Series A
- JB Investment (https://capitalatlas.ai/funds/jb-investment) — Series A
- Shinhan Capital (https://capitalatlas.ai/funds/shinhan-capital) — Series B
- BNH Investment (https://capitalatlas.ai/funds/bnh-investment) — Series B
- Signite (https://capitalatlas.ai/funds/signite) — Series B
- MiCo — Series B